Multivariate analyses describing NRM at 100 days and OS using the HCT comorbidity index, preconditioning CRP, and adjusted EBMT score
| Variable . | No. (%) . | Day 100 NRM . | OS . | ||
|---|---|---|---|---|---|
| HR (95% CI) . | P . | HR (95% CI) . | P . | ||
| HCT-CI | |||||
| 0 | 146 (60) | 1.0 | 1.0 | ||
| 1 or more | 98 (40) | 4.29 (1.8-10.5) | .001 | 1.58 (1.04-2.4) | .03 |
| CRP | |||||
| 0-9 mg/L | 217 (89) | 1.0 | 1.0 | ||
| More than 9 mg/L | 27 (11) | 4.22 (1.6-11.2) | .004 | 2.33 (1.4-4.0) | .002 |
| Data missing | 27 | ||||
| EBMT score | |||||
| 0-1 | 45 (18) | 1.0 | 1.0 | ||
| 2 | 65 (27) | 1.2 (.3-4.9) | .78 | .96 (.5-2.1) | .91 |
| 3 | 87 (36) | 1.5 (.4-5.7) | .50 | 1.6 (.8-3.1) | .18 |
| More than 3 | 47 (19) | 1.1 (.3-4.8) | .89 | 2.1 (1.04-4.4) | .038 |
| Variable . | No. (%) . | Day 100 NRM . | OS . | ||
|---|---|---|---|---|---|
| HR (95% CI) . | P . | HR (95% CI) . | P . | ||
| HCT-CI | |||||
| 0 | 146 (60) | 1.0 | 1.0 | ||
| 1 or more | 98 (40) | 4.29 (1.8-10.5) | .001 | 1.58 (1.04-2.4) | .03 |
| CRP | |||||
| 0-9 mg/L | 217 (89) | 1.0 | 1.0 | ||
| More than 9 mg/L | 27 (11) | 4.22 (1.6-11.2) | .004 | 2.33 (1.4-4.0) | .002 |
| Data missing | 27 | ||||
| EBMT score | |||||
| 0-1 | 45 (18) | 1.0 | 1.0 | ||
| 2 | 65 (27) | 1.2 (.3-4.9) | .78 | .96 (.5-2.1) | .91 |
| 3 | 87 (36) | 1.5 (.4-5.7) | .50 | 1.6 (.8-3.1) | .18 |
| More than 3 | 47 (19) | 1.1 (.3-4.8) | .89 | 2.1 (1.04-4.4) | .038 |
Twenty-seven patients were excluded from the analyses because of lack of CRP data.
NRM indicates nonrelapse mortality; OS, overall survival; HR, hazard ratio; CI, confidence interval; HCT-CI, hematopoietic cell transplantation comorbidity index; CRP, C-reactive protein; and EBMT, European Group for Blood and Marrow transplantation.